Coya Therapeutics Q2 net loss widens as R&D costs rise

Coya Therapeutics

11/08/2026 13:08

Overview
U.S. biotech firm's Q2 collaboration revenue steady yr/yr at $0.2 mln
Q2 net loss widened to $6.6 mln as R&D expenses rose

Outlook
Coya expects to complete ALSTARS Phase 2 ALS trial enrollment in 2H 2026
Company plans to initiate Phase 2 study of COYA 302 in FTD in 2H 2026
Coya says cash is sufficient to fund operations into 2H 2027

Result Drivers
R&D EXPENSES - Co said higher Q2 research and development expenses were mainly due to increased preclinical and clinical product candidate costs for COYA 302 ALS Phase 2 trial
LOWER ADMIN COSTS - Co said general and administrative expenses fell due to reduced professional services and employee compensation

Company press release: ID:nBw9mZ8rca

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.28
 
Q2 Net Loss
 
$6.6 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Coya Therapeutics Inc is $16.00, about 244.8% above its August 10 closing price of $4.64

Reuters Recommended Reads
Aug 11 - Shattuck Labs Q2 net loss widens as R&D spending rises
Aug 11 - Zura Bio Q2 net loss widens as R&D expenses rise
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)